Medical oncology data and global mortality statistics consistently classify cancers such as pancreatic cancer, lung cancer, and liver cancer among the most aggressive and deadliest malignancies. These specific cancer types frequently feature low early-stage detection rates, rapid metastatic progression, and high resistance to conventional therapies, resulting in challenging overall survival prognoses despite continuous advancements in modern surgical and pharmacological treatments.